File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1210/jcem.81.2.8636281
- Scopus: eid_2-s2.0-9044247068
- PMID: 8636281
- WOS: WOS:A1996TU98100038
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone
Title | Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone |
---|---|
Authors | |
Issue Date | 1996 |
Publisher | The Endocrine Society. The Journal's web site is located at http://jcem.endojournals.org |
Citation | Journal of Clinical Endocrinology and Metabolism, 1996, v. 81 n. 2, p. 635-640 How to Cite? |
Abstract | The spontaneous growth process in Turner's syndrome is characterized by a progressive decline in height velocity during childhood and no pubertal growth spurt. Therefore, therapy aimed at improving height during childhood as well as increasing final height is desirable for most girls with Turner's syndrome. Forty-five girls with Turner's syndrome, 9-16 yr of age (mean age, 12.2 yr), were allocated to three study groups. Group 1 (n = 13) was initially treated with oxandrolone alone; after 1 yr of treatment, GH without (group 1a; n = 6) or with (group 1b; n = 7) ethinyl estradiol was added. Group 2 (n = 17) was treated with GH plus oxandrolone. Group 3 (n = 15) was treated with GH, oxandrolone, and ethinyl estradiol. The dosages were: GH, 0.1 IU/kg · day; oxandrolone, 0.05 mg/kg · day; and ethinyl estradiol, 100 ng/kg · day. A height of 150 cm or more was achieved in 61%, 75%, and 60% of the girls in groups 1, 2, and 3, respectively. The most impressive increase in height was seen in group 2. In this group the mean final height was 154.2 cm (SD = 6.6), which is equivalent to a mean net gain of 8.5 cm (SD = 4.6) over the projected final height. In group 3, in which ethinyl estradiol was included from the start of therapy, the initially good height velocity decelerated after 1-2 yr of treatment. Their mean final height was 151.1 (SD = 4.6) cm, equivalent to a mean net gain of 3.0 cm (SD = 3.8). A similar growth-decelerating effect of ethinyl estradiol was seen in group 1b. We conclude that in girls with Turner's syndrome who are older than 9 yr of age, treatment with GH in combination with oxandrolone results in significant growth acceleration, imitating that in normal puberty, leading to a more favorable height during childhood. This mode of treatment also results in a significantly increased final height, permitting a great number of the girls to attain a final height of more than 150 cm. However, early addition of estrogen decelerates the height velocity and reduces the gain in height. |
Persistent Identifier | http://hdl.handle.net/10722/49392 |
ISSN | 2023 Impact Factor: 5.0 2023 SCImago Journal Rankings: 1.899 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nilsson, KO | en_HK |
dc.contributor.author | AlbertssonWikland, K | en_HK |
dc.contributor.author | Alm, J | en_HK |
dc.contributor.author | Aronson, S | en_HK |
dc.contributor.author | Gustafsson, J | en_HK |
dc.contributor.author | Hagenäs, L | en_HK |
dc.contributor.author | Häger, A | en_HK |
dc.contributor.author | Ivarsson, SA | en_HK |
dc.contributor.author | Karlberg, J | en_HK |
dc.contributor.author | Kriström, B | en_HK |
dc.contributor.author | Marcus, C | en_HK |
dc.contributor.author | Moell, C | en_HK |
dc.contributor.author | Ritzén, M | en_HK |
dc.contributor.author | Tuvemo, T | en_HK |
dc.contributor.author | Wattsgård, C | en_HK |
dc.contributor.author | Westgren, U | en_HK |
dc.contributor.author | Westphal, O | en_HK |
dc.contributor.author | Åman, J | en_HK |
dc.date.accessioned | 2008-06-12T06:41:17Z | - |
dc.date.available | 2008-06-12T06:41:17Z | - |
dc.date.issued | 1996 | en_HK |
dc.identifier.citation | Journal of Clinical Endocrinology and Metabolism, 1996, v. 81 n. 2, p. 635-640 | en_HK |
dc.identifier.issn | 0021-972X | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/49392 | - |
dc.description.abstract | The spontaneous growth process in Turner's syndrome is characterized by a progressive decline in height velocity during childhood and no pubertal growth spurt. Therefore, therapy aimed at improving height during childhood as well as increasing final height is desirable for most girls with Turner's syndrome. Forty-five girls with Turner's syndrome, 9-16 yr of age (mean age, 12.2 yr), were allocated to three study groups. Group 1 (n = 13) was initially treated with oxandrolone alone; after 1 yr of treatment, GH without (group 1a; n = 6) or with (group 1b; n = 7) ethinyl estradiol was added. Group 2 (n = 17) was treated with GH plus oxandrolone. Group 3 (n = 15) was treated with GH, oxandrolone, and ethinyl estradiol. The dosages were: GH, 0.1 IU/kg · day; oxandrolone, 0.05 mg/kg · day; and ethinyl estradiol, 100 ng/kg · day. A height of 150 cm or more was achieved in 61%, 75%, and 60% of the girls in groups 1, 2, and 3, respectively. The most impressive increase in height was seen in group 2. In this group the mean final height was 154.2 cm (SD = 6.6), which is equivalent to a mean net gain of 8.5 cm (SD = 4.6) over the projected final height. In group 3, in which ethinyl estradiol was included from the start of therapy, the initially good height velocity decelerated after 1-2 yr of treatment. Their mean final height was 151.1 (SD = 4.6) cm, equivalent to a mean net gain of 3.0 cm (SD = 3.8). A similar growth-decelerating effect of ethinyl estradiol was seen in group 1b. We conclude that in girls with Turner's syndrome who are older than 9 yr of age, treatment with GH in combination with oxandrolone results in significant growth acceleration, imitating that in normal puberty, leading to a more favorable height during childhood. This mode of treatment also results in a significantly increased final height, permitting a great number of the girls to attain a final height of more than 150 cm. However, early addition of estrogen decelerates the height velocity and reduces the gain in height. | en_HK |
dc.format.extent | 418 bytes | - |
dc.format.mimetype | text/html | - |
dc.language | eng | en_HK |
dc.publisher | The Endocrine Society. The Journal's web site is located at http://jcem.endojournals.org | en_HK |
dc.relation.ispartof | Journal of Clinical Endocrinology and Metabolism | en_HK |
dc.subject.mesh | Anabolic Agents - therapeutic use | en_HK |
dc.subject.mesh | Body Height | en_HK |
dc.subject.mesh | Growth Hormone - therapeutic use | en_HK |
dc.subject.mesh | Oxandrolone - therapeutic use | en_HK |
dc.subject.mesh | Turner Syndrome - drug therapy - physiopathology | en_HK |
dc.title | Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Karlberg, J: jpekarl@hkucc.hku.hk | en_HK |
dc.identifier.authority | Karlberg, J=rp00400 | en_HK |
dc.description.nature | link_to_OA_fulltext | en_HK |
dc.identifier.doi | 10.1210/jcem.81.2.8636281 | en_HK |
dc.identifier.pmid | 8636281 | - |
dc.identifier.scopus | eid_2-s2.0-9044247068 | en_HK |
dc.identifier.hkuros | 10116 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-9044247068&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 81 | en_HK |
dc.identifier.issue | 2 | en_HK |
dc.identifier.spage | 635 | en_HK |
dc.identifier.epage | 640 | en_HK |
dc.identifier.isi | WOS:A1996TU98100038 | - |
dc.publisher.place | United States | en_HK |
dc.identifier.scopusauthorid | Nilsson, KO=7202864742 | en_HK |
dc.identifier.scopusauthorid | AlbertssonWikland, K=19639814800 | en_HK |
dc.identifier.scopusauthorid | Alm, J=24340617700 | en_HK |
dc.identifier.scopusauthorid | Aronson, S=7202182723 | en_HK |
dc.identifier.scopusauthorid | Gustafsson, J=36014564800 | en_HK |
dc.identifier.scopusauthorid | Hagenäs, L=7003589762 | en_HK |
dc.identifier.scopusauthorid | Häger, A=7005597215 | en_HK |
dc.identifier.scopusauthorid | Ivarsson, SA=7004869731 | en_HK |
dc.identifier.scopusauthorid | Karlberg, J=7005218406 | en_HK |
dc.identifier.scopusauthorid | Kriström, B=6603784721 | en_HK |
dc.identifier.scopusauthorid | Marcus, C=7103039681 | en_HK |
dc.identifier.scopusauthorid | Moell, C=6701489079 | en_HK |
dc.identifier.scopusauthorid | Ritzén, M=7004087512 | en_HK |
dc.identifier.scopusauthorid | Tuvemo, T=7004294160 | en_HK |
dc.identifier.scopusauthorid | Wattsgård, C=6602244234 | en_HK |
dc.identifier.scopusauthorid | Westgren, U=7004173770 | en_HK |
dc.identifier.scopusauthorid | Westphal, O=7005030214 | en_HK |
dc.identifier.scopusauthorid | Åman, J=7006018152 | en_HK |
dc.identifier.issnl | 0021-972X | - |